NEODOSE

INDICATIONS

Phosphate supplementation: After administration of sodium glycerophosphate 1.5 mmol/kg/day, mean increases in plasma phosphorus concentrations were 0.33+/-0.08 mmol/L at 12 hours, 0.72 +/-0.3 mmol/L at 36 hours, and 0.9+/-0.3 mmol/L at 60 hours (p less than 0.0001 for all values) from a baseline of less than 0.5 mmol/L in a retrospective report of very low birthweight neonates with hypophosphatemia receiving parenteral nutrition (n=19; mean gestational age 28+/-3 weeks). All patients had been receiving parenteral nutrition solutions with inorganic calcium and phosphorus salts at the limit of solubility when hypophosphatemia resulted. The switch to sodium glycerophosphate as the sole phosphorus source not only increased the amount of phosphorus that could be administered each day, but also allowed an increase in the amount of calcium infused to 1.5 mmol/kg/day. By 60 hours, all patients had achieved a plasma phosphorus concentration of 1.5 mmol/L or greater.

FDA APPROVED INDICATION

Because of the critical shortage of phosphate injection in the United States market, an alternative imported formulation of Glycophos™ has been made available; however, it is not approved by the US Food and Drug Administration.

CONTRAINDICATIONS

Contraindicated in patients with dehydration, hypernatremia, hyperphosphatemia, severe renal insufficiency, or shock. Product contains 2 mEq/mL of sodium. Use with caution in patients with renal impairment . Barcodes on the Glycophos™ product will not be recognized by scanning systems used in the US and should not be used. The product should be manually input into the system. Alternate procedures should be put in place to assure that the correct drug product is being prepared and administered to the patient .

ADVERSE EFFECTS

No adverse effects of sodium glycerophosphate have been reported.

ADMINISTRATION

Must be diluted before administration. Administer over no less than 8 hours.

MONITORING

Regularly monitor phosphate status.